H2020FP7HORIZON
Novartis Pharma AG
- Country
- CHSwitzerland
- Projects
- 85
- As coordinator
- 8
- EU contribution (CORDIS)
- EUR 2,998,017
- Active
- 2008 to 2025
Projects
85 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| READIResearch in Europe and Diversity Inclusion | HORIZON | 2025 | Participant | EUR 0 |
| Chiral-BetaAsymmetric carbyne catalytic transfer to streamline synthesis of chiral β-amino carbonyls | HORIZON | 2025 | Associated partner | EUR 0 |
| NHPigReducing Non-Human Primates in Non-Clinical Safety Assessment: The European Initiative on Minipig and Micropig Models | HORIZON | 2024 | Participant | EUR 0 |
| MetRaZymesMetal-containing Radical Enzymes | HORIZON | 2022 | Associated partner | EUR 0 |
| EPNDEuropean platform for neurodegenerative disorders | H2020 | 2021 | Participant | EUR 0 |
| HIPPOCRATESHealth Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States | H2020 | 2021 | Participant | EUR 0 |
| PharmaLedgerPharmaLedger | H2020 | 2020 | Participant | EUR 0 |
| CHAIRC-H Activation for Industrial Renewal | H2020 | 2020 | Participant | EUR 0 |
| INNODIA HARVESTTranslational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA | H2020 | 2020 | Participant | EUR 0 |
| H2OH2O Health Outcomes Observatory | H2020 | 2020 | Participant | EUR 0 |
| ImmUniverseBetter control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies | H2020 | 2020 | Participant | EUR 0 |
| PREMIERPrioritisation and Risk Evaluation of Medicines in the EnviRonment | H2020 | 2020 | Participant | EUR 0 |
| EU-PEARLEU Patient- cEntric clinicAl tRial pLatform | H2020 | 2019 | Participant | EUR 0 |
| MOBILISE-DConnecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement | H2020 | 2019 | Participant | EUR 0 |
| RADAR-ADRemote Assessment of Disease and Relapse – Alzheimer’s Disease | H2020 | 2019 | Participant | EUR 0 |
| NeuroDeRiskNeurotoxicity De-Risking in Preclinical Drug Discovery | H2020 | 2019 | Participant | EUR 0 |
| MELLODDYMachinE Learning Ledger Orchestration for Drug DiscoverY | H2020 | 2019 | Participant | EUR 0 |
| NECESSITYNEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients | H2020 | 2019 | Participant | EUR 0 |
| Trials@HomeTrials@Home: Center of Excellence – Remote Decentralised Clinical Trials | H2020 | 2019 | Participant | EUR 0 |
| FAIRplusFAIRplus | H2020 | 2019 | Participant | EUR 0 |
The country is the one the source records for the organisation’s registration (its PIC). A body with sites in several countries is recorded under one of them, which is not always its legal seat: the Spanish research council CSIC, for example, appears under Italy. The data holds no country per site, so we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.